← 產業報告目錄

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-06-27頁數 329報告編號 PH9404

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market's development. The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period. Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics. In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume. The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030. The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (70%) and Demand Side (30%) • By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) List of Key Companies Profiled in the Report: F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others. Research Coverage: This research report categorizes the ophthalmology drugs market by molecule (aflibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market. Key Benefits of Buying the Report: The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: • Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment). • Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market. • Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.
目錄 Table of Contents
1 INTRODUCTION 31 1.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.3 STUDY SCOPE 32 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32 1.3.2 INCLUSIONS & EXCLUSIONS 33 1.3.3 YEARS CONSIDERED 34 1.3.4 CURRENCY CONSIDERED 34 1.4 STAKEHOLDERS 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 36 2.1.1.1 Objectives of secondary research 36 2.1.1.2 Key data from secondary sources 37 2.1.2 PRIMARY DATA 37 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 38 2.1.2.2 Key objectives of primary research 38 2.2 MARKET ESTIMATION METHODOLOGY 39 2.2.1 GLOBAL MARKET ESTIMATION 39 2.2.1.1 Product revenue analysis (bottom-up approach) 39 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc. 40 2.2.1.3 MnM repository analysis 41 2.2.1.4 Primary interviews 41 2.2.2 INSIGHTS OF PRIMARY EXPERTS 41 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH) 42 2.3 MARKET GROWTH RATE PROJECTIONS 43 2.4 DATA TRIANGULATION 45 2.5 STUDY ASSUMPTIONS 45 2.6 RESEARCH LIMITATIONS 46 2.7 RISK ANALYSIS 46 3 EXECUTIVE SUMMARY 47 4 PREMIUM INSIGHTS 51 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW 51 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 52 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024 52 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 5.2 MARKET DYNAMICS 54 5.2.1 DRIVERS 55 5.2.1.1 Aging population and growing prevalence of vision disorders 55 5.2.1.2 Strong drug pipeline and growing innovation efforts 56 5.2.1.3 Increasing investments and strategic collaborations 57 5.2.1.4 Improved reimbursement policies 57 5.2.2 RESTRAINTS 58 5.2.2.1 Off-label drug use for various indications 58 5.2.3 OPPORTUNITIES 59 5.2.3.1 Shifting focus on new drug modalities 59 5.2.3.2 Expansion into emerging markets 60 5.2.3.3 High unmet needs 61 5.2.4 CHALLENGES 61 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment 61 5.3 TECHNOLOGY ANALYSIS 62 5.3.1 KEY TECHNOLOGIES 63 5.3.1.1 Hybridoma technology 63 5.3.1.2 Recombinant DNA technology 63 5.3.1.3 Antibody engineering 64 5.3.1.4 Gene therapy 64 5.3.1.5 Nanoformulations 65 5.3.2 ADJACENT TECHNOLOGIES 65 5.3.2.1 Optogenetic technology 65 5.3.2.2 Drug-release technologies 66 5.3.2.3 Ocular implant technologies 66 5.3.3 COMPLEMENTARY TECHNOLOGIES 66 5.3.3.1 3D printing and bioprinting 66 5.3.3.2 Ocular imaging technologies 67 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67 5.5 PRICING ANALYSIS 67 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024 68 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024 68 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024 69 5.6 VALUE CHAIN ANALYSIS 69 5.7 ECOSYSTEM ANALYSIS 71 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS 72 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES 73 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS 74 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES 74 5.8 PATENT ANALYSIS 75 5.9 REGULATORY ANALYSIS 76 5.9.1 REGULATORY LANDSCAPE 76 5.9.1.1 US 77 5.9.1.2 Europe 78 5.9.1.3 Emerging markets 78 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 5.10 PORTER’S FIVE FORCES ANALYSIS 82 5.10.1 INTENSITY OF COMPETITIVE RIVALRY 84 5.10.2 BARGAINING POWER OF SUPPLIERS 84 5.10.3 BARGAINING POWER OF BUYERS 84 5.10.4 THREAT OF SUBSTITUTES 84 5.10.5 THREAT OF NEW ENTRANTS 85 5.11 KEY CONFERENCES & EVENTS, 2025–2026 85 5.12 REIMBURSEMENT SCENARIO 86 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 86 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS 87 5.14 INVESTMENT & FUNDING SCENARIO 88 5.15 PIPELINE ANALYSIS 89 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET 92 5.16.1 CHALLENGES IN DRUG DISCOVERY 93 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS 93 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET 94 5.17.1 KEY TARIFF RATES 94 5.17.2 PRICE IMPACT ANALYSIS 95 5.17.3 KEY IMPACT ON VARIOUS REGIONS 96 5.17.3.1 US 96 5.17.3.2 Europe 96 5.17.3.3 APAC 96 5.17.4 MANUFACTURING INDUSTRY IMPACT 97 5.17.4.1 Ophthalmology drug manufacturers 97 6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 98 6.1 INTRODUCTION 99 6.2 AFLIBERCEPT 99 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH 99 6.3 FARICIMAB 102 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH 102   6.4 RANIBIZUMAB 105 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION 105 6.5 OTHER MOLECULES 108 7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY 112 7.1 INTRODUCTION 113 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS 113 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET 113 7.3 SMALL MOLECULES 116 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET 116 7.4 OTHER MODALITIES 119 8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION 123 8.1 INTRODUCTION 124 8.2 AGE-RELATED MACULAR DEGENERATION 124 8.2.1 WET AGE-RELATED MACULAR DEGENERATION 127 8.2.1.1 Increasing demand for effective therapies to drive market 127 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION 130 8.2.2.1 Large market opportunity for innovation to drive growth 130 8.3 DIABETIC RETINOPATHY (DR) 131 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES 131 8.4 DIABETIC MACULAR EDEMA (DME) 133 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET 133 8.5 OTHER INDICATIONS 136 9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 139 9.1 INTRODUCTION 140 9.2 INTRAVITREAL 140 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET 140 9.3 TOPICAL 143 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS 143 9.4 OTHER ROUTES OF ADMINISTRATION 145 10 OPHTHALMOLOGY DRUGS MARKET, BY END USER 148 10.1 INTRODUCTION 149 10.2 HOSPITALS 149 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH 149 10.3 LONG-TERM CARE FACILITIES 152 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET 152 10.4 SPECIALTY CENTERS 154 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH 154 11 OPHTHALMOLOGY DRUGS MARKET, BY REGION 158 11.1 INTRODUCTION 159 11.2 NORTH AMERICA 159 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160 11.2.2 US 164 11.2.2.1 Rising investments in healthcare research and development to support growth 164 11.2.3 CANADA 167 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth 167 11.3 EUROPE 170 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 170 11.3.2 GERMANY 175 11.3.2.1 Rising focus on clinical research to drive market 175 11.3.3 UK 178 11.3.3.1 Ongoing advancements in technology to drive market growth 178 11.3.4 FRANCE 181 11.3.4.1 Growing investments and government support to drive market growth 181 11.3.5 ITALY 183 11.3.5.1 Growing investments and research to support market 183 11.3.6 SPAIN 186 11.3.6.1 Growing geriatric population to drive market growth 186 11.3.7 REST OF EUROPE 189 11.4 ASIA PACIFIC 191 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 191 11.4.2 CHINA 195 11.4.2.1 Large diabetic population to boost market 195 11.4.3 JAPAN 198 11.4.3.1 Growing aging population to intensify demand for effective treatments 198 11.4.4 INDIA 201 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market 201 11.4.5 AUSTRALIA 203 11.4.5.1 Strong biopharmaceutical sector to drive market growth 203 11.4.6 SOUTH KOREA 206 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth 206 11.4.7 REST OF ASIA PACIFIC 209   11.5 LATIN AMERICA 211 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 211 11.5.2 BRAZIL 215 11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments 215 11.5.3 MEXICO 218 11.5.3.1 Growing research initiatives and innovations to support market growth 218 11.5.4 REST OF LATIN AMERICA 221 11.6 MIDDLE EAST 224 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 224 11.6.2 GCC COUNTRIES 227 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth 227 11.6.3 REST OF MIDDLE EAST 230 11.7 AFRICA 233 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH 233 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 233 12 COMPETITIVE LANDSCAPE 237 12.1 INTRODUCTION 237 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 237 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET 237 12.3 REVENUE ANALYSIS, 2022–2024 238 12.4 MARKET SHARE ANALYSIS, 2024 239 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024 242 12.5.1 STARS 242 12.5.2 EMERGING LEADERS 242 12.5.3 PERVASIVE PLAYERS 242 12.5.4 PARTICIPANTS 242 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 244 12.5.5.1 Company footprint 244 12.5.5.2 Region footprint 245 12.5.5.3 Molecule footprint 246 12.5.5.4 Modality footprint 247 12.5.5.5 Indication footprint 248 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 249 12.6.1 PROGRESSIVE COMPANIES 249 12.6.2 RESPONSIVE COMPANIES 249 12.6.3 DYNAMIC COMPANIES 249 12.6.4 STARTING BLOCKS 249   12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 251 12.6.5.1 Detailed list of key startups/SMEs 251 12.6.5.2 Competitive benchmarking of startups/SMEs 252 12.7 COMPANY VALUATION & FINANCIAL METRICS 253 12.7.1 VALUATION OF KEY PLAYERS 253 12.7.2 FINANCIAL METRICS OF KEY PLAYERS 253 12.8 BRAND/PRODUCT COMPARISON 254 12.9 COMPETITIVE SCENARIO 255 12.9.1 PRODUCT LAUNCHES & APPROVALS 255 12.9.2 DEALS 256 13 COMPANY PROFILES 257 13.1 KEY PLAYERS 257 13.1.1 REGENERON PHARMACEUTICALS INC. 257 13.1.1.1 Business overview 257 13.1.1.2 Products offered 258 13.1.1.3 Recent developments 259 13.1.1.3.1 Product approvals 259 13.1.1.4 MnM view 259 13.1.1.4.1 Right to win 259 13.1.1.4.2 Strategic choices 259 13.1.1.4.3 Weaknesses & competitive threats 260 13.1.2 F. HOFFMANN-LA ROCHE LTD. 261 13.1.2.1 Business overview 261 13.1.2.2 Products offered 262 13.1.2.3 Recent developments 263 13.1.2.3.1 Product launches & approvals 263 13.1.2.4 MnM view 264 13.1.2.4.1 Right to win 264 13.1.2.4.2 Strategic choices 264 13.1.2.4.3 Weaknesses & competitive threats 265 13.1.3 BAYER AG 266 13.1.3.1 Business overview 266 13.1.3.2 Products offered 267 13.1.3.3 Recent developments 268 13.1.3.3.1 Product approvals 268 13.1.3.4 MnM view 268 13.1.3.4.1 Right to win 268 13.1.3.4.2 Strategic choices 269 13.1.3.4.3 Weaknesses & competitive threats 269   13.1.4 NOVARTIS AG 270 13.1.4.1 Business overview 270 13.1.4.2 Products offered 271 13.1.4.3 Recent developments 272 13.1.4.3.1 Product approvals 272 13.1.4.3.2 Deals 272 13.1.4.4 MnM view 273 13.1.4.4.1 Right to win 273 13.1.4.4.2 Strategic choices 273 13.1.4.4.3 Weaknesses & competitive threats 273 13.1.5 ABBVIE 274 13.1.5.1 Business overview 274 13.1.5.2 Products offered 275 13.1.6 APELLIS PHARMACEUTICALS 276 13.1.6.1 Business overview 276 13.1.6.2 Products offered 277 13.1.6.3 Recent developments 278 13.1.6.3.1 Product approvals 278 13.1.6.3.2 Deals 278 13.1.7 BIOGEN 279 13.1.7.1 Business overview 279 13.1.7.2 Products offered 280 13.1.7.3 Recent developments 281 13.1.7.3.1 Product launches & approvals 281 13.1.8 BAUSCH + LOMB 283 13.1.8.1 Business overview 283 13.1.8.2 Products offered 285 13.1.8.3 Recent developments 287 13.1.8.3.1 Product launches & approvals 287 13.1.9 ASTELLAS PHARMA INC. 288 13.1.9.1 Business overview 288 13.1.9.2 Products offered 289 13.1.9.3 Recent developments 290 13.1.9.3.1 Product approvals 290 13.1.9.3.2 Deals 290 13.1.10 FORMYCON AG 291 13.1.10.1 Business overview 291 13.1.10.2 Products offered 292 13.1.10.3 Recent developments 293 13.1.10.3.1 Product launches & approvals 293 13.1.10.3.2 Deals 294   13.1.11 BIOCON 295 13.1.11.1 Business overview 295 13.1.11.2 Products offered 296 13.1.11.3 Recent developments 296 13.1.11.3.1 Product approvals 296 13.1.11.3.2 Deals 296 13.1.12 SANDOZ GROUP AG 297 13.1.12.1 Business overview 297 13.1.12.2 Products offered 298 13.1.12.3 Recent developments 299 13.1.12.3.1 Product approvals 299 13.1.12.3.2 Deals 299 13.1.13 SANTEN PHARMACEUTICAL CO., LTD. 300 13.1.13.1 Business overview 300 13.1.13.2 Products offered 301 13.1.13.3 Recent developments 302 13.1.13.3.1 Product launches 302 13.1.14 INNOVENT 303 13.1.14.1 Business overview 303 13.1.14.2 Products offered 304 13.1.14.3 Recent developments 304 13.1.14.3.1 Product approvals 304 13.1.15 OUTLOOK THERAPEUTICS, INC. 305 13.1.15.1 Business overview 305 13.1.15.2 Products offered 305 13.1.15.3 Recent developments 306 13.1.15.3.1 Product approvals 306 13.1.15.3.2 Deals 306 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 307 13.1.16.1 Business overview 307 13.1.16.2 Products offered 308 13.1.16.3 Recent developments 309 13.1.16.3.1 Product approvals 309 13.1.16.3.2 Deals 310 13.2 OTHER PLAYERS (PIPELINE COMPANIES) 311 13.2.1 OCULAR THERAPEUTIX, INC. 311 13.2.2 OPTHEA LIMITED 312 13.2.3 KODIAK SCIENCES INC. 313 13.2.4 EYEPOINT PHARMACEUTICALS, INC. 314 13.2.5 ALVOTECH 315 13.2.6 CLEARSIDE BIOMEDICAL 316   13.2.7 SHANGHAI HENLIUS BIOTECH, INC. 317 13.2.8 ADVERUM BIOTECHNOLOGIES, INC. 318 13.2.9 REMEGEN 319 13.2.10 SPARINGVISION 320 14 APPENDIX 321 14.1 DISCUSSION GUIDE 321 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325 14.3 CUSTOMIZATION OPTIONS 327 14.4 RELATED REPORTS 327 14.5 AUTHOR DETAILS 328
圖表清單 List of Tables & Figures
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 44 TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS 46 TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS 55 TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024 68 TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024 69 TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS 72 TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES 73 TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS 74 TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES 74 TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024 75 TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 83 TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS 85 TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 87 TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER 87 TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025) 90 TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 94 TABLE 22 EXPORTS AND IMPORTS, BY REGION 95 TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 99 TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 113 TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 124 TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 125 TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION) 134 TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION) 138 TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 140 TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 149 TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION) 157 TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORS 160 TABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 162 TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 162 TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 163 TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 163 TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 164 TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 165 TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 165 TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 166 TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 166 TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 167 TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 168 TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 168 TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 168 TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 169 TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 169 TABLE 156 EUROPE: MACROECONOMIC INDICATORS 171 TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 173 TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 173 TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 174 TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 174 TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 176 TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 176 TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 177 TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 177 TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 178 TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 179 TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 179 TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 179 TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 180 TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 180 TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 181 TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 182 TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 182 TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 182 TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 183 TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 183 TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 184 TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 184 TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 185 TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 185 TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 187 TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 187 TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 187 TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 188 TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 188 TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 189 TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 190 TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 190 TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 191 TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 191 TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS 193 TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 193 TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 194 TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 194 TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 195 TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 196 TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 196 TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 197 TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 197 TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 199 TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 199 TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 199 TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 200 TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 200 TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 201 TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 202 TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 202 TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 203 TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 204 TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 204 TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 205 TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 205 TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 207 TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 207 TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 207 TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 208 TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 208 TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 209 TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 210 TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 210 TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 210 TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 211 TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 211 TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS 212 TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 213 TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 213 TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 213 TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 214 TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 214 TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 215 TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 216 TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 216 TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 217 TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 217 TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 217 TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 218 TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 219 TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 219 TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 220 TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 220 TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 221 TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 222 TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 222 TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 223 TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 223 TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 223 TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS 225 TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 225 TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 226 TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 226 TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 226 TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 227 TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 227 TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 228 TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 228 TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 228 TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 229 TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 229 TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 230 TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 231 TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 231 TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 232 TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 289 AFRICA: MACROECONOMIC INDICATORS 234 TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 234 TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 234 TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 235 TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 235 TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET 237 TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION 240 TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT 245 TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT 246 TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT 247 TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT 248 TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 251 TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 252 TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025 255 TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022–MAY 2025 256 TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW 257 TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED 258 TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 259 TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 261 TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 262 TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 263 TABLE 312 BAYER AG: COMPANY OVERVIEW 266 TABLE 313 BAYER AG: PRODUCTS OFFERED 267 TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 268 TABLE 315 NOVARTIS AG: COMPANY OVERVIEW 270 TABLE 316 NOVARTIS AG: PRODUCTS OFFERED 271 TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 272 TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2025 272 TABLE 319 ABBVIE: COMPANY OVERVIEW 274 TABLE 320 ABBVIE: PRODUCTS OFFERED 275 TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW 276 TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED 277 TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 278 TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2025 278 TABLE 325 BIOGEN: COMPANY OVERVIEW 279 TABLE 326 BIOGEN: PRODUCTS OFFERED 280 TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 281 TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW 283 TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED 285 TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 287 TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 288 TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 289 TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 290 TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–JULY 2024 290 TABLE 335 FORMYCON AG: COMPANY OVERVIEW 291 TABLE 336 FORMYCON AG: PRODUCTS OFFERED 292 TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 293 TABLE 338 FORMYCON AG: DEALS, JANUARY 2021–MAY 2025 294 TABLE 339 BIOCON: COMPANY OVERVIEW 295 TABLE 340 BIOCON: PRODUCTS OFFERED 296 TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 296 TABLE 342 BIOCON: DEALS, JANUARY 2021–MAY 2025 296 TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW 297 TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED 298 TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 299 TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021–JULY 2024 299 TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 300 TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED 301 TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025 302 TABLE 350 INNOVENT: COMPANY OVERVIEW 303 TABLE 351 INNOVENT: PRODUCTS OFFERED 304 TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 304 TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW 305 TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED 305 TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 306 TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022–MAY 2025 306 TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 307 TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 308 TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 309 TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025 310 TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW 311 TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW 312 TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW 313 TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW 314 TABLE 365 ALVOTECH: COMPANY OVERVIEW 315 TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW 316 TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW 317 TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 318 TABLE 369 REMEGEN: COMPANY OVERVIEW 319 TABLE 370 SPARINGVISION: COMPANY OVERVIEW 320 FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE 32 FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN 35 FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES 37 FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38 FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 39 FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024) 40 FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024) 40 FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 41 FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH 42 FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS 43 FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION 45 FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION) 47 FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION) 48 FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION) 48 FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION) 49 FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 49 FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET 50 FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH 51 FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024 52 FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD 52 FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD 53 FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67 FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024 68 FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS 70 FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS 72 FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024) 75 FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 83 FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY 86 FIGURE 30 KEY BUYING CRITERIA FOR END USERS 87 FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT 161 FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT 172 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 239 FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 240 FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 243 FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT 244 FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 250 FIGURE 38 EV/EBITDA OF KEY PLAYERS 253 FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS 253 FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 254 FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024) 258 FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 262 FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024) 267 FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024) 271 FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024) 275 FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 277 FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024) 280 FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024) 284 FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024) 289 FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024) 292 FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024) 295 FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024) 298 FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024) 301 FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024) 303 FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 308

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們